Evidence map›Paper›PMID 38747227›Full record

ArticleCurrent cancer drug targets2025

New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.

Mohammad Hamza Heriz, Ammar A Razzak Mahmood, Lubna H Tahtamouni, Mai F Al-Sakhen, Sana I Kanaan, Khaled M Saleh, Salem R Yasin

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad Hamza HerizDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Al-Zahraa University for Women, Karbala-Baghdad Street, Karbala, Iraq.
Ammar A Razzak MahmoodDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Bab-Almoudam, 10001, Baghdad, Iraq.
Lubna H TahtamouniDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Mai F Al-SakhenDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Sana I KanaanDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Khaled M SalehDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Salem R YasinDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.

Funding

Deanship of Scientific Research, Hashemite University, Jordan 111/2022
6 · The paper itself

Abstract

INTRODUCTION/

backgroundBecause of the well-established link between angiogenesis and tumor development, the use of antiangiogenic therapeutics, such as those targeting VEGFR-2, presents a promising approach to cancer treatment. In the current study, a set of five hydrazine-1- carbothioamide (compounds 3a-e) and three hydrazine-1-carboxamide derivatives (compounds 4a-c) were successfully synthesized from 3-phenoxybenzoic acid. These compounds were specially created as antiproliferative agents with the goal of targeting cancer cells by inhibiting VEGFR- 2 tyrosine kinase. MATERIALS AND

methodsThe new derivatives were synthesized by conventional organic methods, and their structure was versified by IR,

resultsThe designed derivatives exhibited comparable binding positions and interactions to the VEGFR-2 binding site to that of sorafenib (a standard VEGFR-2 tyrosine kinase inhibitor), as determined by molecular docking analysis. Compound 4b was the most cytotoxic compound, achieving the lowest IC

conclusionOverall, the findings suggest that compound 4b has a promising future as a starting point for the development of new anticancer drugs.

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsThioamidesVascular Endothelial Growth Factor Receptor-2ApoptosisCell Line, TumorCell ProliferationHeLa CellsHep G2 CellsHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsKDR protein, humanProtein Kinase InhibitorsThioamidesVascular Endothelial Growth Factor Receptor-23-Phenoxybenzoic acidapoptosisenzyme assay.in silicopharmacophoreVEGFR-2

Identifiers

PMID38747227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.